USE OF HUMAN PRIMARY CELLS FOR DISCOVERY OF NOVEL CANCER THERAPEUTICS
Research type
Research Study
Full title
Use of Human Primary cells for the discovery of Novel antibody therapeutics in the treatment of Cancer
IRAS ID
238022
Contact name
Anderson Ryan
Contact email
Sponsor organisation
Fast Biopharma Ltd
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
2 years, 11 months, 30 days
Research summary
Fast Biopharma Ltd aims to provide innovative experimental therapeutics for the treatment of cancer. The current focus is on using the natural immune response to fight tumours. Recent progress in the understanding of the mechanisms behind cancer’s strategies to defeat the immune system have already led to drugs, that by inhibiting Immune Checkpoints can successfully treat immunogenic tumours. However, not all patients respond to these therapies and new ways of boosting the immune system’s ability to conquer cancer are needed.
FastBiopharma Ltd have identified a different Immune Checkpoint and are currently developing a therapeutic antibody against this target.The candidate therapeutic antibodies will initially be screened in cell based assays using characterised mammalian cell lines to model the mode of action of the antibody as closely as possible. However, the use of cell lines does not represent the functional characteristics of the target cells as closely as using primary cells. Assays using primary cells will be developed to model the mode of action of the Antibody as closely as possible in order to develop a robust understanding of the efficacy of the proposed therapeutic antibodies.
Fast Biopharma Ltd is therefore proposing to isolate primary cells from anonymised human blood. Samples will be taken from healthy volunteers and used for functional assays and toxicity screening of proposed therapeutic
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
18/NW/0069
Date of REC Opinion
16 Jan 2018
REC opinion
Favourable Opinion